Adult Dosing
Chronic hepatitis C infection
Monotherapy
- Initial: 9 mcg SC x 3/wk x 24 wks or retreatment: 15 mcg SC x 3/wk x 48 wks
Combination therapy (for body wt <75 kg and 
75 kg)
- 15 mcg/day SC with ribavirin 1,000 or 1,200 mg/day x 48 wks (as retreatment)
Note: Reduce dosage if patient experiences serious adverse reactions
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
Renal Dose Adjustment (Based on CrCl)
- <50 mL/min: Combination therapy not recommended
Hepatic Dose Adjustment
- Child-Pugh score >6 [class B and C]: Contraindicated
- Therapy may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor closely for such disorders and suspend therapy if such severe or worsening signs or symptoms occur [US Black Box Warning]
- Therapy is not recommended in pregnant females and female partners of male patients, as ribavirin may cause birth defects and fetal death [US Black Box Warning]
- Ribavarin use has been associated with hemolytic anemia which may worsen cardiac disease [US Black Box Warning]
- Prior to initiating therapy, female patients must have a negative pregnancy test, at least 2 forms of contraception should be used, and monthly pregnancy tests should be performed because therapy may cause birth defects and fetal death with ribavirin
- Closely monitor patients and reduce dosage accordingly in neuropsychiatric disorders, renal Insufficiency, cardiovascular events, autoimmune disorders, bone marrow toxicity
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
- Use with ribavirin
- Neuropsychiatric disorders
- Cardiovascular events
- Pulmonary disorders
- Cerebrovascular disorders
- Bone marrow toxicity
- Colitis
- Pancreatitis
- Autoimmune disorders
- Ophthalmologic disorders
- Peripheral neuropathy
- Endocrine disorders
Pregnancy Category:C; Combination therapy: X
Breastfeeding: Safety unknown. The amount of the drug excreted in milk is very low. Any interferon in breastmilk is probably destroyed in the infant's gastrointestinal tract and not absorbed, except perhaps in neonates. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 10 May 2011). Maternal medication usually compatible with breastfeeding, no observable change was seen in the nursing infant while the mother was ingesting the compound. This information is based upon data from AAP Policy Guidelines (available at http://aappolicy.aappublications.org/cgi/content/full/pediatrics;108/3/776/T6 last accessed 10 May 2011). Due to the potential for serious adverse reactions in nursing infants, manufacturer recommends discontinuation of nursing or discontinuation of drug, taking into account the importance of the drug to the mother.
Pricing data from www.DrugStore.com in U.S.A.
- Infergen 15 MCG/0.5ML INJ [Vial] (KADMON PHARMACEUTICALS)
0.5 0.5ml = $120.99
1.5 0.5ml = $331.12
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
